Search review questions

Good neurological outcome · adults after cardiopulmonary resuscitation

Survival · adults after cardiopulmonary resuscitation

Adverse events – pneumonia · adults after cardiopulmonary resuscitation

Adverse events – hypokalaemia · adults after cardiopulmonary resuscitation

Adverse events – arrhythmia · adults after cardiopulmonary resuscitation

All‐cause mortality: all ECMO studies · severe cardiorespiratory failure and cardiac arrest

All‐cause mortality: VV ECMO subgroup · severe cardiorespiratory failure and cardiac arrest

All‐cause mortality: VA ECMO subgroup · severe cardiorespiratory failure and cardiac arrest

All‐cause mortality: ECPR subgroup · severe cardiorespiratory failure and cardiac arrest

Major hemorrhage: all available studies · severe cardiorespiratory failure and cardiac arrest

Neurologic injury: all available studies · severe cardiorespiratory failure and cardiac arrest

All‐cause mortality: range 1 mo to 1 y · adults admitted to the ICU

Proportion of participants with ≥ 1 serious adverse events according to International Conference on Harmonisation Good Clinical Practice: range 3 d to 180 d · adults admitted to the ICU

Quality of life (any measure): range 180 d to 1 y · adults admitted to the ICU

Lung injury diagnosed after randomisation (composite outcome): range 4 d to 23 d · adults admitted to the ICU

Myocardial infarction diagnosed after randomisation: range ≤ 90 d · adults admitted to the ICU

Stroke diagnosed after randomisation: range 1 mo to 3 mo · adults admitted to the ICU

Sepsis diagnosed after randomisation: range 28 d to 60 d · adults admitted to the ICU

Hospital stay · people requiring tracheal intubation

Incidence of severe hypoxaemia (SpO2 < 80%) · people requiring tracheal intubation

Incidence of hypoxaemia (SpO2 < 93%) · people requiring tracheal intubation

Lowest recorded SpO2 (%) · people requiring tracheal intubation

ICU stay (days) · people requiring tracheal intubation

First pass success rate · people requiring tracheal intubation

Adverse eventse · people requiring tracheal intubation

Mortality · people requiring tracheal intubation

Outcomes, Time point of assessment · relatives, patients, and healthcare professionals during resucitation

PTSD in the relatives IES (0 to 75; > 30 = presence of PTSD) measured at 3 months and > 3 months · relatives, patients, and healthcare professionals during resucitation

Anxiety and depression in the relatives HADS (0 to 42; subscale score > 10 (range, 0 to 21) = presence of anxiety or depression) measured at 3 months and > 3 months · relatives, patients, and healthcare professionals during resucitation

Grief in the relatives ICG (0 to 95; > 25 = presence of complicated grief) measured at 12 months TRIG (21 to 105; lower scores indicate higher levels of grief) measured at 3 and 9 months · relatives, patients, and healthcare professionals during resucitation

 · relatives, patients, and healthcare professionals during resucitation

Survival of patients · relatives, patients, and healthcare professionals during resucitation

Duration of resuscitation in minutes · relatives, patients, and healthcare professionals during resucitation

Stress intensity in the medical team members VAS (0 to 100; 0 = no stress; 100 = maximum stress)Â · relatives, patients, and healthcare professionals during resucitation

Clinical improvement D28b · people with mild/moderate/severe/critical COVID‐19

WHO progression score (level 7 or above) D28 · people with mild/moderate/severe/critical COVID‐19

All‐cause mortality D28 · people with mild/moderate/severe/critical COVID‐19

All‐cause mortality D60 or more · people with mild/moderate/severe/critical COVID‐19

Adverse events ( · people with mild/moderate/severe/critical COVID‐19

Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19

Clinical improvement D28b · people with mild/moderate/severe/critical COVID‐19

Clinical improvement D60 or more · people with mild/moderate/severe/critical COVID‐19

WHO progression score (level 7 or above) D28 · people with mild/moderate/severe/critical COVID‐19

All‐cause mortality D28 · people with mild/moderate/severe/critical COVID‐19

All‐cause mortality D60 or more · people with mild/moderate/severe/critical COVID‐19

Clinical improvement D60 or moref · people with mild/moderate/severe/critical COVID‐19

Adverse events ( · people with mild/moderate/severe/critical COVID‐19

Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19

Clinical improvement D28b · people with mild/moderate/severe/critical COVID‐19

Clinical improvement D60 or more ‐ not reported · people with mild/moderate/severe/critical COVID‐19